Portal de Periódicos da CAPES

Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening

2005; Elsevier BV; Volume: 13; Issue: 22 Linguagem: Inglês

10.1016/j.bmc.2005.06.043

1464-3391

Laura Novaroli, Marianne Reist, Elisabeth Favre, Angelo Carotti, Marco Catto, Pierre‐Alain Carrupt,

Parkinson's Disease Mechanisms and Treatments

Interest in inhibitors of monoamine oxidase type B (MAO B) has grown in recent years, due to their therapeutic potential in aging-related neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. This study is devoted to the use of human recombinant MAO B obtained from a Baculovirus expression system (Supersomes™ MAO B, BD Gentest, MA, USA) as reliable and efficient enzyme source for MAO B inhibitor screening. Comparison of inhibition potencies (pIC50 values) determined with human cloned and human platelet MAO B for the two series of MAO B inhibitors, coumarin and 5H-indeno[1,2-c]pyridazin-5-one derivatives, showed that the difference between pIC50 values obtained with the two enzyme sources was not significant (P > 0.05, Student's t-test). Hence, recombinant enzyme is validated as convenient enzyme source for MAO B inhibitor screening.